In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions

Lung Cancer. 2002 Feb;35(2):155-63. doi: 10.1016/s0169-5002(01)00411-1.

Abstract

Forty-four specimens of non-malignant and malignant human lung tissue, taken from patients with non-small cell lung cancer (NSCLC), were examined for the expression of wild-type p53, mutant p53, and bcl-2 and the occurrence of programmed cell death (apoptosis). Wild-type p53 expression peaked in peritumoral and metaplastic samples, whereas mutant p53, bcl-2 and apoptosis were first detected in metaplasia and increased with progression to carcinoma. Bcl-2 positive samples had lower levels of apoptosis than bcl-2 negative samples and was independent of wild-type or mutant p53 expression. These results suggest that the over-expression of wild-type p53 may be an early cellular response to an alteration in normal cellular homeostasis. The ensuing increase in apoptosis appears to be relatively independent of mutant or wild-type p53 expression, but does not occur in cells expressing bcl-2.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Apoptosis*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / physiopathology*
  • Gene Expression Regulation, Neoplastic*
  • Homeostasis
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / physiopathology*
  • Precancerous Conditions / genetics*
  • Precancerous Conditions / physiopathology*
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 / biosynthesis*

Substances

  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Suppressor Protein p53